Skip to content
    DB

    Dawn Biopharma

    New York, New York, United StatesFounded 2022
    LinkedIn
    Biotech & Life SciencesHealthcare

    Dawn Biopharma is an investment platform controlled by the KKR Healthcare Strategic Growth Fund II, established to own and support a diverse portfolio of companies committed to the development of innovative medicines and therapies. It provides flexible capital to companies across the life sciences ecosystem.

    83% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 3 prior). Their most common stage is series-a (44% of deals). Average disclosed round size is $94.4M (across 13 rounds with reported amounts).

    Find people at Dawn Biopharma on Goldilocks AI

    Portfolio

    8

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    2

    Team

    IR

    Iyona Rajkomar

    Managing Partner

    DM

    Donnie McCarthy

    Principal

    Portfolio Breakdown

    Stage Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    18 investments
    CompanyRoundAmountDate
    AAgomabSeries A$100MSep 2026
    Agomab Therapeutics logoAgomab TherapeuticsSeries D$89MSep 2026
    Adcendo ApS logoAdcendo ApSSeries C$75MApr 2026
    Vedana Therapeutics logoVedana TherapeuticsSeries A$46MJan 2026
    Adcytherix logoAdcytherixSeries A—Oct 2025
    Antag Therapeutics logoAntag TherapeuticsSeries A—Dec 2024
    Adcendo ApS logoAdcendo ApSSeries B$135MNov 2024
    Bambusa Therapeutics logoBambusa TherapeuticsSeed$15MSep 2024
    Adcytherix logoAdcytherixSeed—Jun 2024
    Antag Therapeutics logoAntag TherapeuticsSeries A—Jan 2024
    Adcendo ApS logoAdcendo ApSSeries B$135MJan 2024
    AAgomabSeries B$100MOct 2023
    AAgomabSeries C$100MOct 2023
    Adcendo ApS logoAdcendo ApSSeries A$17.3MApr 2021
    Adcendo ApS logoAdcendo ApSSeries B$135MJan 2021
    Expedition Therapeutics logoExpedition TherapeuticsSeries B$115M—
    Expedition Therapeutics logoExpedition TherapeuticsSeries A$165M—
    Antag Therapeutics logoAntag TherapeuticsSeries A——

    Top Co-Investors

    Novo Capital8 shared
    Pontifax7 shared
    RA Capital Management7 shared
    Logos Capital6 shared
    Surveyor Capital5 shared
    Venrock Healthcare Capital Partners5 shared
    GG15 shared
    Novo Holdings A/S5 shared
    Ysios Capital5 shared
    OrbiMed5 shared
    HealthCap5 shared
    Gilde Healthcare5 shared
    Canaan Partners5 shared
    KKR4 shared
    EQT Life Sciences4 shared
    Fidelity Management & Research Company4 shared
    Sanofi Ventures3 shared
    TPG Life Sciences Innovations3 shared
    SR One3 shared
    EIFO3 shared

    Last updated: 27 September 2026